ITOS News and Press, iTeos Therapeutics Inc. From 03/23/22

iTeos Therapeutics press release (NASDAQ:ITOS): Q4 GAAP EPS of -$5.24. The Company’s cash and cash equivalent position was $848.5 million as of December 31, 2021, as compared to $336.3 million as of December 31, 2020. Cash balance provides runway into 2026. For further details see: ...

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab -gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combination - Initiati...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, to...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

The stock market got off to a memorable start on the first trading day of 2022, but iTeos Therapeutics (NASDAQ: ITOS) had a particularly memorable day. Shares of the clinical-stage biotech rose by 1.9% to beat the frothy S&P 500 on the day, thanks to its inclusion in another...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

iTeos Therapeutics Set to Join S&P SmallCap 600 iTeos Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , Dec. 31, 2021 /PRNewswire/ -- iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&...

Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combination with an immunomodulatory drug in patients with multiple myeloma Preclinica...

iTeos Therapeutics Inc. (ITOS) Q3 2021 Earnings Conference Call November 10, 2021 04:30 PM ET Company Participants Ryan Baker - Head-IR Michel Detheux - President and CEO Matthew Gall - CFO Joe Lager - CMO Conference Call Participants Daina Graybosch - SVB Leerink Anupam Rama - JP Morgan Davi...